Lorapam

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorapam

This foundational section provides essential identity and classification details for Lorapam, which contains the active substance Lorazepam.

Property Description
Active Ingredient Lorazepam
Primary Form Tablets, Oral Solution, Injectable Solution
Pharmacological Class Benzodiazepine (CNS Depressant)
General Purpose Relieves acute tension, promotes quietude
Origin Synthetic (Derivative)

What Pharmacological Class Does Lorapam Belong To?

Lorapam is a single-ingredient synthetic medicinal product containing the active substance Lorazepam, which belongs to the benzodiazepine pharmacological class. This classification identifies it as a Central Nervous System (CNS) depressant. The drug's action is generally recognized in pharmacological studies for its effects on regulating and reducing excessive excitability within the brain's neural network. Other widely recognized products containing the same active ingredient include Ativan and Loreev XR.

Lorazepam: Active Ingredient and Product Forms

The sole active component is Lorazepam. The medicine is presented across multiple dosage forms, including conventional tablets and oral concentrate solution for ingestion, as well as specialized sterile solutions prepared for parenteral use via intravenous (IV) or intramuscular (IM) injection. This diverse presentation is supported by clinical consensus for facilitating administration based on required speed of action. The availability of multiple forms ensures appropriate delivery for different clinical requirements, accommodating either gradual onset via the oral route or rapid onset via injection.

What is the General Purpose of This Medicine?

The general purpose of this medicine is to promote mental quietude and relieve excessive physical and emotional tension. For instance, it is typically used to manage acute, disruptive states of apprehension. Lorapam functions by modulating the activity of the inhibitory neurotransmitter Gamma-aminobutyric acid (GABA) in the central nervous system. This action slows down overactive nerve signals in the brain, leading directly to the core benefit of inducing relaxation and reducing states of acute stress or worry.

What side effects are possible with Lorapam?

The official safety profile of Lorapam (Lorazepam) is documented in government regulatory sources and is categorized by frequency and the physiological systems affected.

Adverse Reaction Scope

The adverse reactions most frequently reported are linked to the medicine's role as a Central Nervous System (CNS) depressant.

Component Description
Frequency Classification Very Common: Drowsiness, Sedation. Common: Ataxia (unsteadiness), Dizziness, Muscle weakness, Fatigue. Rare: Confusion, Depression, Hypotension, Jaundice, Transient anterograde amnesia.
System-Organ Classes Nervous System Disorders, Psychiatric Disorders, General Disorders, Respiratory Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Key Constraints

Specific serious safety issues are highlighted in regulatory labeling, independent of frequency:

  • Respiratory Depression and Apnoea: A potentially fatal risk, especially when the medicine is used with other CNS depressants such as opioids.
  • Severe Hypersensitivity: Rare, but documented reactions include anaphylaxis and angioedema (swelling of the face, tongue, or larynx).
  • Dependence and Withdrawal: The risk of physical and psychological dependence increases with longer treatment duration. Abrupt cessation may precipitate acute, potentially life-threatening withdrawal reactions, including seizures.
  • Population-Specific Safety: Older adults have increased susceptibility to sedative effects, increasing the risk of falls. Severe hepatic insufficiency is a formal contraindication due to the risk of precipitating encephalopathy.
  • Paradoxical Reactions: Behavioral disturbances, including hostility, aggression, and rage, have been reported and may be more likely in older adults and children.

Connection to the Overall Safety Profile

The official safety profile structures the understanding of risks by defining the high probability of common CNS-related effects and clearly delineating less frequent but critical safety concerns, such as severe respiratory depression and hypersensitivity. This framework separates expected reactions from critical safety constraints and exposure-related risks like dependence.

Overdose and Emergency Response

The official regulatory documents state that Lorapam overdose is primarily characterized by a deepening spectrum of Central Nervous System (CNS) depression. Initial manifestations include somnolence, confusion, ataxia, and lethargy. As severity increases, the depression can progress to more serious clinical findings, specifically hyporeflexia, profound sedation, and life-threatening conditions such as respiratory depression and coma. Death is documented, particularly in cases of massive overdose or when the medicine is consumed alongside other CNS depressants, notably alcohol. Regulatory notes specify that elderly patients and those with existing respiratory issues may be more sensitive to these CNS depressant effects.

Regulators mandate that immediate medical attention must be sought for any suspected overdose. Management is uniformly described as symptomatic and supportive treatment, emphasizing the critical need to maintain a patent airway, support ventilation, and monitor cardiovascular function. Continuous monitoring of vital signs is required until the patient’s condition is stable. While a specific antagonist, Flumazenil, is mentioned in official labeling, its use is generally cautioned against due to the documented risk of precipitating seizures, thus its administration is reserved for specific, severe clinical scenarios.

Therapeutic Uses of Lorapam

What Lorapam Treats: Main Uses and Benefits

Lorapam provides supportive relief by targeting conditions and episodes marked by symptoms related to heightened physiological activity and increased emotional distress. The medication may assist with promoting mental quietude and supports the management of acute, challenging symptoms. In clinical practice, the medication is commonly used across key therapeutic domains.

The medication is used across conditions and scenarios where short-term symptomatic assistance is appropriate, including severe acute anxiety and tension, continuous convulsive seizures, supportive relief during alcohol withdrawal syndrome, and anxiety-driven insomnia.

“It is commonly used when symptoms intensify and supportive relief is needed, assisting with the management of distress and physical tension.”

This use is relevant for managing pronounced feelings of apprehension, worry, and physical restlessness that create noticeable physiological strain. The medication may be part of symptomatic management in acute care settings for managing continuous convulsive seizure manifestations (status epilepticus) and is applied for managing severe, uncontrollable behavioral agitation. It is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Acute Anxiety and Tension, Continuous Seizures, and Alcohol Withdrawal Symptoms

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lorapam

Official regulatory documents define strict criteria for the use of Lorapam (Lorazepam) across different patient populations.

Category Regulatory Status Details
Absolute Contraindications MUST NOT USE Known hypersensitivity to benzodiazepines or the formulation's components, acute narrow-angle glaucoma, and Myasthenia Gravis (in some regions).
Age-Related Rules Not Established / Caution Safety and effectiveness are not established in children under 12 years of age (oral tablets). Elderly or debilitated patients require special caution and a carefully adjusted, usually lower, initial dose.
Life Stage Not Recommended Use is not recommended during pregnancy (especially late stages) or breastfeeding due to potential risks to the infant.
Condition-Specific Restrictions Caution / Contraindicated Patients with severe hepatic insufficiency require caution as use may worsen hepatic encephalopathy; in some regions, this is a contraindication. Severe respiratory insufficiency or sleep apnea syndrome are often contraindications due to the risk of respiratory depression.
Mental Health Context Not Recommended Lorapam is not recommended as sole therapy for patients with a primary depressive disorder or psychosis.

The eligibility structure is primarily defined by high-risk contraindications and populations where the drug's safety is not established (pediatric age group). Short-term use is generally allowed for the approved adult population, but use is restricted to short periods only (e.g., 2–4 weeks), as long-term efficacy has not been evaluated.

What should I know about interactions with other medicines?

The most serious drug interaction involves the concomitant use of lorazepam with opioids, including opioid analgesics and cough medicines containing opioids. This combination carries a significant risk of profound sedation, respiratory depression, coma, and death due to their additive depressant effects on the central nervous system (CNS). Due to these risks, co-prescribing is officially reserved only for patients when alternative treatments are inadequate, using the lowest effective dosages for minimum durations.

Lorazepam also produces increased CNS depressant effects when administered with other CNS depressants, such as alcohol, barbiturates, antipsychotics, antidepressants, sedative antihistamines, and anesthetics. A specific notable interaction is with clozapine, which may produce marked sedation, excessive salivation, and potentially respiratory arrest.

Two specific medicines, valproate and probenecid, interact by inhibiting the metabolic process of lorazepam known as glucuronidation. This inhibition leads to increased plasma concentrations and reduced clearance of lorazepam, resulting in increased effects. For coadministration with either valproate or probenecid, regulatory guidelines stipulate that the lorazepam dosage should be reduced by approximately 50%.

Mechanism of Action

Modulation of the Core Inhibitory Pathway

Lorapam's mechanism centers on the GABA-A receptor complex, the primary site for inhibitory signaling in the brain. The drug acts as a positive allosteric modulator, binding to a specific site on the receptor to enhance the effects of the body's natural inhibitory neurotransmitter, GABA. This interaction increases the frequency of chloride ion (Cl^-) channel openings, driving negative ions into the nerve cell.

Global Neuronal Stabilization

The enhanced Cl^- influx causes nerve cells to become hyperpolarized, increasing the threshold required for them to fire an electrical signal. This widespread stabilization reduces overall neuronal excitability across the central nervous system, particularly in regions like the limbic system. This dampening effect modulates overactive neural output, leading to the core physiological consequence of widespread CNS inhibition and dampening of motor system output.

Mechanism Limitations: GABA-Dependence

Crucially, the drug's mechanism is GABA-dependent; Lorapam cannot activate the receptor in the absence of the natural neurotransmitter. Furthermore, prolonged enhancement of this mechanism can trigger neuroadaptive changes, such as receptor uncoupling, where the effectiveness of Lorapam's potentiation is reduced, illustrating a key limitation in sustained receptor engagement.

Dosage and Administration Information

How to Use Lorapam

This section outlines the general principles and standardized patterns for administering Lorapam (Lorazepam). The information focuses strictly on routes, dosing schedules, and preparation requirements.


Administration and Dosing Principles

The medicine is approved for Oral, Intravenous (IV), and Intramuscular (IM) use, enabling administration via tablets, oral concentrate, or sterile injection. The choice of administration route depends on the required speed of action and clinical context. Oral forms, including immediate-release tablets, are typically taken in divided doses, commonly two or three times daily for anxiety, while the dose for insomnia is a single daily dose at bedtime. The total daily dose for anxiety in adults typically starts at 2 to 3 mg and can range up to 10 mg.

IV administration for acute conditions like status epilepticus involves a standardized initial dose of 4 mg, which is infused at a controlled rate, not exceeding 2 mg per minute.


Key Administration Constraints

Official instructions mandate specific handling for certain forms. The oral concentrate must be diluted immediately prior to ingestion with a liquid or soft food like juice or applesauce, and the mixture must not be stored. Similarly, the injectable solution often requires dilution with an equal volume of a compatible solution before IV administration. Oral forms can generally be taken with or without food.

For older or debilitated adults, the starting daily dose is significantly reduced, often to 1 to 2 mg in divided doses, and the initial dose should generally not exceed 2 mg. Treatment is typically limited to short periods (e.g., up to four weeks for anxiety), and discontinuation requires a gradual tapering of the dose to avoid abrupt cessation effects.

Recent Clinical Evidence

Research evidence / Overview of studies for Lorapam

Evidence for Short-Term Anxiety and Tension Relief

Research on Lorapam was studied for its use in conditions characterized by fluctuating or episodic manifestations of anxiety. Studies exploring how symptoms change over time mainly consisted of short-term Randomized Controlled Trials (RCTs). These trials enrolled adult patients and used standardized clinical assessment scales to monitor outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort related to worry.

Findings described patterns observed in the studies where measured symptom levels were tracked, including comparisons with placebo. Studies reported observations related to changes in anxiety measures over the observed time interval. However, these reported outcomes reflected measurements taken only during the acute phase of treatment.


Evidence for Acute Conditions: Seizures and Alcohol Withdrawal

Lorapam was evaluated in settings involving acute or disruptive episodes, particularly for continuous convulsive seizures (status epilepticus) and the alcohol withdrawal syndrome (AWS).

For status epilepticus, the evidence primarily comes from comparative RCTs and systematic reviews involving both adults and pediatric populations. Research examined the time to cessation of seizure activity and the sustained absence of convulsions, as well as the need for additional medication. In the adult population, studies reported that the measured outcomes related to seizure cessation were observed in a high percentage of participants. For pediatric patients, the findings varied, and some studies reported observed measurements related to the monitored outcomes were not consistent across all age groups.


Study Duration and Long-Term Research Gaps

A significant research boundary is the general focus on short-term relief, with follow-up durations being limited across the core evidence base. For the short-term relief of anxiety, for instance, limited data are still emerging for the effects of use beyond a few weeks. The usefulness has not been systematically assessed in trials exceeding four months.

The evidence highlights what is known about immediate relief and acute crisis management, but long-term effects are not fully established by systematic clinical studies. This means that the research has not determined the effects or duration of response when the medicine is used continuously for many months, creating an area where data are still emerging or insufficient.


What is Still Uncertain About Lorapam Research

A primary limitation is that there is limited information for long-term outcomes across all indications, as the majority of follow-up durations were limited to acute or short-term periods (e.g., a few weeks). Comparative evidence is lacking in certain areas, such as robust head-to-head trials against non-benzodiazepine treatments for alcohol withdrawal.

Finally, evidence quality varies across studies, especially when examining specific endpoints like mortality or long-term neurological health following status epilepticus. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Lorazepam not superior to diazepam in pediatric status epilepticus | MDedge
  2. COMPARATIVE EFFICACY AND SAFETY OF PHARMACOTHERAPIES FOR ALCOHOL WITHDRAWAL: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS - NIH

Frequently Asked Questions (FAQ)

Common questions about Lorapam (FAQ)

Q: Do regulatory bodies list any specific black box warnings for Lorapam?

Regulatory documents from bodies like the FDA include a prominent warning, also known as a Boxed Warning, for Lorapam. This official warning focuses on the serious risks associated with the co-use of Lorapam and opioid medicines, and highlights the risks of abuse, misuse, and physical dependence.


Q: Can Lorapam affect a person's ability to drive or operate machinery?

Official warnings describe that operating heavy machinery or driving motor vehicles should be avoided. This is because Lorapam may cause effects such as sedation, dizziness, blurred vision, or difficulty concentrating, which could potentially impair judgment and physical abilities.


Q: What is the typical duration of action for Lorapam?

The duration of the main effects, such as reducing anxiety and inducing quietude, is generally reported to be six to eight hours after a single dose. Additionally, the time it takes for half the active substance to be cleared from the blood, known as the half-life, is approximately 12 hours.


Q: How long does Lorapam stay in the body after the last dose?

The complete elimination of the active drug and its major inactive forms from the body typically occurs within about one week following the last dose. This duration reflects group patterns and may not be the same for every individual.


Q: Does Lorapam interact with hormonal contraceptives?

Official information indicates that some oral hormonal contraceptives may increase the rate at which the body clears Lorapam. Regulatory documents describe the need for close observation for any signs of an altered effect of Lorapam when these medicines are used together.


Q: Does Lorapam have known interactions with common herbal supplements?

Official patient information states that individuals should inform their healthcare provider about all herbal products and supplements they are taking. Some herbal remedies, particularly those intended for anxiety or sleeplessness, may increase Lorapam's overall drowsy or sedating effects.


Q: Does Lorapam cause weight gain or weight loss?

Clinical studies and official safety profiles for Lorapam do not commonly list changes in body weight, whether gain or loss, as a directly reported side effect of the medicine itself. The official adverse reaction tables focus primarily on Central Nervous System effects.


Q: Are there any known interactions between Lorapam and common foods or drinks (like grapefruit)?

Lorapam tablets may generally be taken with or without food. Official sources indicate that Lorapam, unlike some other medicines, does not appear to be affected by enzyme-inhibiting substances sometimes found in foods like grapefruit.


Q: Are there specific instructions for what to do if a dose of Lorapam is forgotten?

Official guidance describes that if a dose is missed, the dose is generally taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If so, the missed dose is skipped. The guidance specifies that a double dose is not to be taken to make up for the forgotten one.


Q: What is the official information regarding Lorapam and breastfeeding?

Official information generally describes that the use of Lorapam is not recommended during the breastfeeding period. This is because the active substance or its inactive forms may pass into breast milk, posing potential risks for the infant, such such as sedation or poor feeding.


Q: Why is Lorapam sometimes described as a short-term use medicine?

Regulatory guidance often limits the use of Lorapam to short periods, such as two to four weeks. This is primarily because the efficacy for use beyond four months has not been systematically assessed in clinical studies, and the risk of physical dependence increases significantly with longer treatment duration.


Q: How does Lorapam generally interact with alcohol?

The combination with alcohol produces increased Central Nervous System (CNS) depressant effects. Regulatory warnings describe that the consumption of alcohol should be avoided while taking Lorapam due to the heightened risk of deep sedation, breathing problems, and impaired coordination.


Q: Can taking Lorapam affect routine blood test results?

Regulatory documents state that for patients using Lorapam for a long period, periodic monitoring through blood counts and liver function tests is stipulated. This is because certain changes, such as in white blood cell counts (leukopenia) or liver enzyme levels, have been observed in some cases.


Q: What are the reported themes regarding Lorapam's effects on memory?

The official safety profile lists transient anterograde amnesia (a temporary period of forgetfulness) as a rare reaction. Due to the medicine's overall depressive effect on the Central Nervous System, the potential for general forgetfulness is also sometimes noted in patient information.


Q: Why is Lorapam a prescription-only medicine?

Lorapam is a prescription-only medicine because it is classified as a Schedule IV Controlled Substance by regulatory agencies. This classification means the drug has a potential for abuse, misuse, and the development of physical and psychological dependence, which places it under strict professional management.


Q: Are there specific lifestyle factors (like caffeine or smoking) that interact with Lorapam?

Official drug interaction sections primarily focus on other medicines and alcohol. Specific warnings regarding common stimulants like caffeine or nicotine (smoking) are not universally highlighted across primary regulatory warnings for this medicine.


Q: What distinguishes Lorapam from other drugs used for anxiety?

Lorapam belongs to the benzodiazepine pharmacological class. Its distinguishing action is its direct binding to the GABA-A receptor in the brain, which rapidly enhances inhibitory signaling. This mechanism leads quickly to widespread Central Nervous System inhibition, reducing acute tension.


Q: Is Lorapam used for conditions other than the ones listed in official documents?

Regulatory documents define the medicine's approved uses (indications). Use for purposes not listed in these official documents is considered outside the scope of regulatory approval. The efficacy for such non-approved uses has not been systematically evaluated by the agencies.


Q: Can Lorapam be used by individuals with kidney or liver issues?

Official warnings advise special caution for individuals with severe hepatic (liver) insufficiency because use may worsen a condition called hepatic encephalopathy. While caution is generally advised for all medical conditions, specific safety information regarding general kidney issues is not consistently highlighted across major regulatory documents.


Q: Can Lorapam be taken with common cold and flu medications?

Many common cold and flu medications contain ingredients such as antihistamines or cough suppressants, which act as Central Nervous System (CNS) depressants. Combining Lorapam with other CNS depressants is officially warned against due to the risk of increased sedation and respiratory depression.


Q: How do regulatory documents describe the long-term risks of Lorapam?

The main long-term risks described include the increased likelihood of developing physical and psychological dependence and the potential for withdrawal reactions if the medicine is abruptly stopped. Official documents also note that the effectiveness of the drug has not been systematically assessed in studies exceeding four months.


Q: Is Lorapam available in different forms or only as a tablet?

Lorapam is available in multiple forms. These include oral tablets, an oral concentrate solution for ingestion, and a specialized sterile solution prepared for injection, which allows for either intravenous or intramuscular administration.


Q: Why do some people experience initial drowsiness when starting Lorapam?

Drowsiness and sedation are listed as very common effects. This is directly related to the medicine's fundamental mechanism of action, which causes widespread Central Nervous System (CNS) inhibition by slowing down overactive nerve signals in the brain, leading to a state of relaxation.


Q: Is it normal for the effect of Lorapam to feel less noticeable over time?

Official information indicates that the prolonged use of Lorapam can lead to tolerance. This is a process where the body adapts to the drug, which may potentially result in a reduced response or the effect feeling less noticeable over time.

How should Lorapam be stored and disposed of?

How to Store and Dispose of Lorapam?

The official storage conditions for lorazepam vary by dosage form. Tablets require storage at controlled room temperature (20 C to 25 C) and must be kept in a tightly closed container away from moisture and heat. The oral concentrate solution and injectable solution must be stored under refrigeration (2 C to 8 C) and protected from light; the oral concentrate must be discarded 90 days after opening.

As a Schedule IV Controlled Substance, lorazepam must be stored in a secure, locked area, and kept strictly out of the sight and reach of children.

Unused or expired product should be disposed of via a drug take-back program. If no program is available, the medicine is disposed of in household trash by mixing it with an undesirable substance (such as dirt or coffee grounds) and sealing it in a container, per federal guidelines. The medicine must not be flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorapam found in:

A-Z Index: